Author

Martha D. Port

Observed names: M. Port, MD Port, Martha Port, Port, Martha

Institution: Eli Lilly (United States)

Observed institution: Eli Lilly (United States)

ORCID: 0000-0001-6559-1014

Observed ORCID: 0000-0001-6559-1014

OpenAlex ID: A5034262571

Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials

2019 · Li Shen Loo, Jessica Ailani, et al. · The Journal of Headache and Pain · 43

Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial

2021 · Uwe Reuter, Christian Lucas, et al. · Advances in Therapy · 39

Changes in migraine interictal burden following treatment with galcanezumab: Results from a phase III randomized, placebo‐controlled study

2023 · Richard B. Lipton, Dawn C. Buse, et al. · Headache The Journal of Head and Face Pain · 27

Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized clinical trials

2020 · Virginia L. Stauffer, Ira Turner, et al. · The Journal of Headache and Pain · 20

Does “wearing off” of efficacy occur in galcanezumab‐treated patients at the end of the monthly treatment cycle? Post hoc analyses of four phase III randomized trials

2022 · Jessica Ailani, Dulanji K. Kuruppu, et al. · Headache The Journal of Head and Face Pain · 14

Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine

2020 · Janet H. Ford, Tobias Kurth, et al. · Headache The Journal of Head and Face Pain · 13

Interictal Burden of Migraine: Correlations with Other Measures of Migraine Burden and Effects of Galcanezumab Migraine-Preventive Treatment (1914)

2021 · Claire Sandoe, Richard Lipton, et al. · Neurology · 5

P.019 Interictal burden of migraine: correlations with other measures of migraine burden and effects of galcanezumab migraine-preventive treatment

2022 · CH Sandoe, RB Lipton, et al. · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · 1

Chronic pain treatment satisfaction in musculoskeletal disease: differences between osteoarthritis and chronic low back pain in medication switching, opioid use, and utilization of non-pharmacologic treatments

2019 · J. Mali, J. Nascimento, et al. · Osteoarthritis and Cartilage · 1

Does Wearing-Off of Efficacy Occur in Galcanezumab-Treated Patients at the End of the Monthly Treatment Cycle: A Post Hoc Analysis of Four Phase 3 Randomized Trials (1922)

2021 · Jessica Ailani, Dulanji Kuruppu, et al. · Neurology

Effect of Age on Efficacy and Safety of Galcanezumab Treatment in Adult Patients with Migraine (P2.10-021)

2019 · Virginia L. Stauffer, Ira Turner, et al. · Neurology

Patient Gains in Daily Functioning and Reductions in Disability with Galcanezumab among Patients with Episodic and Chronic Migraine (P1.10-003)

2019 · Dustin Ruff, Janet Ford, et al. · Neurology

Works count: 15

Citation count: 163

H-index: 6

I10-index: 6